Stock Report

All about this stock under one free report Last Updated: 03-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Concord Biotech Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: CONCORDBIO | BSE: 543960

₹1,374.10

up-down-arrow ₹0.50 (0.04%)

As on 01-Oct-2026IST

Market cap

info icon

₹14,385 Cr

Revenue (TTM)

info icon

₹1,108 Cr

P/E Ratio

info icon

52.2

P/B Ratio

info icon

6.9

Div. Yield

info icon

0.5 %

Edit peer-selector-edit
Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Market cap (₹ Cr)
 14,385 36,872 27,580 16,849 13,556
Revenue (₹ Cr)
 1,108 9,683 2,372 2,590 676
Net Profit (₹ Cr)
 270.18 1,018.97 497.77 603.02 183.60
Net Margin (%)
 23.29 10.47 20.72 22.63 26.06
RoE (%)
 14.45 21.30 28.49 19.61 22.72
Price to Earnings
 52.24 36.46 55.41 27.94 74.22
Price-To-Book
 6.94 7.05 13.64 4.83 14.67

Income Statement (₹ Cr)

Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Operating Revenue arrow
1,108.39 9,683.45 2,371.81 2,590.40 675.61
Total Income arrow
1,159.90 9,730.84 2,402.61 2,664.23 704.48
Total Expenditure arrow
720.01 7,739.53 1,608.91 1,753.71 442.67
EBITDA arrow
388.38 1,943.92 762.90 836.69 232.94
Depreciation arrow
74.78 425.10 98.11 78.88 15.56
EBIT arrow
313.60 1,518.82 664.79 757.81 217.38
Interest arrow
0.26 148.45 26.33 5.43 7.96
Other Income arrow
51.50 47.39 30.80 73.83 28.87
Exceptional Items arrow
-3.28 -27.85 0.00 -25.66 0.00
Profit before Tax arrow
361.56 1,389.91 669.26 800.55 238.30
Provision for Tax arrow
91.39 370.94 171.48 197.53 54.69
Profit after Tax arrow
270.18 1,018.97 497.77 603.02 183.60

Liabilities (₹ Cr)

Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Shareholder's Funds arrow
2,017.06 4,950.03 1,874.47 3,332.13 883.34
Minority Interest arrow
2.51 -7.58 0.00 0.00 -0.97
Non-Current Liabilities arrow
50.51 723.57 345.47 142.73 74.82
Current Liabilities arrow
169.08 3,912.24 710.20 508.04 201.96
Total Liabilities arrow
2,231.79 9,514.48 2,930.14 4,157.10 1,174.38

Assets (₹ Cr)

Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Non-Current Assets arrow
957.22 3,392.16 1,290.62 1,321.38 477.92
Current Assets arrow
1,250.11 5,612.10 1,483.13 2,649.36 623.97
Total Assets arrow
2,231.79 9,514.48 2,930.14 4,157.10 1,174.38
Total Debt* arrow
0.00 1,204.08 196.61 0.00 148.29
Net Current Assets arrow
1,081.04 1,699.86 772.93 2,141.33 422.01
Contingent Liabilities arrow
3.76 258.92 13.18 4.82 --

Cashflow (₹ Cr)

Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Cash From Operating Activities arrow
266.88 943.55 346.68 565.41 69.55
Cash Flow from Investing Activities arrow
-142.72 -1,193.06 -423.73 -570.15 -330.93
Cash from Financing Activities arrow
-112.88 343.43 20.98 -64.34 247.29
Net Cash Inflow / Outflow arrow
11.28 93.92 -56.08 -69.08 -14.09

Ratios

Profitability Ratios

 Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
ROCE (%) arrow
18.04 25.25 27.50 24.61 28.50
ROE (%) arrow
14.45 21.30 28.49 19.61 22.72
ROA (%) arrow
12.66 11.42 19.48 16.31 31.25
EBIT Margin (%) arrow
28.29 15.68 28.03 29.25 32.18
Net Margin (%) arrow
23.29 10.47 20.72 22.63 26.06
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Revenue Growth (%) arrow
-6.72 18.36 78.33 7.93 23.56
EBIT Growth (%) arrow
-26.64 30.43 303.07 19.88 12.00
Net Profit Growth (%) arrow
-24.38 32.39 182.61 21.66 20.07
EPS Growth (%) arrow
-21.99 36.68 277.72 25.42 50.65
Book Value Growth (%) arrow
11.27 11.36 22.95 18.43 79.97

Valuation Ratios

 Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Price / Earnings arrow
51.78 35.71 55.41 27.06 71.34
Price / Book Value arrow
6.94 7.05 13.64 4.83 14.67
Dividend Yield (%) arrow
0.55 0.19 0.16 0.36 0.13
EV/EBITDA arrow
35.97 19.51 35.94 19.20 58.34
Market Cap (₹ Cr) arrow
10,627.92 30,257.56 15,412.11 11,956.86 6,690.53

Solvency Ratios

 Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.04
Short term debt to equity ratio arrow
-- 0.16 -- -- 0.12
Current Ratio arrow
7.39 1.43 2.09 5.21 3.09
Quick Ratio arrow
5.46 0.82 1.37 3.85 2.02
Interest Coverage arrow
1,386.30 10.36 26.41 148.49 30.94

Operating Efficiency Ratios

 Concord Biotech Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Sudeep Pharma
Debtors to sales (%) arrow
41.52 26.46 22.82 41.42 33.68
Asset Turnover arrow
0.52 1.09 0.93 0.70 1.15
Receivable days arrow
169.86 88.68 77.32 144.58 115.16
Inventory Days arrow
97.92 84.11 80.83 96.67 96.15
Payable days arrow
159.68 176.65 125.94 135.45 106.08
Cash Conversion Cycle arrow
108.11 -3.86 32.22 105.80 105.23
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...